Company Overview of Agensys, Inc.
Agensys, Inc. specializes in research and development of therapeutic fully human monoclonal antibodies and antibody drug conjugates for treatment of cancers. It develops products to treat cancer indications, including those of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company is developing AGS-1C4D4 to treat prostate, pancreatic, and bladder cancers; AGS-5ME for multiple epithelial tumors; AGS-16M8F for the treatment of metastatic renal cancer; and AGS-22M6E for multiple solid tumors including breast, bladder, lung, and pancreatic cancers. Agensys, Inc. was formerly known as UroGenesys, Inc. and changed its name to Agensys, Inc. in June 2001. The comp...
2225 Colorado Avenue
Santa Monica, CA 90404
Founded in 1996
Key Executives for Agensys, Inc.
Chief Executive Officer and President
Chief Medical Officer and Senior Vice President
Corporate Secretary and Corporate Counsel
Vice President of Business Development
Compensation as of Fiscal Year 2013.
Agensys, Inc. Key Developments
Seattle Genetics and Agensys Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration
Jun 27 13
Seattle Genetics Inc. and Agensys, Inc. that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME. ASG-15ME is an ADC composed of a fully human antibody directed to SLITRK6, an antigen expressed in multiple solid tumors. Preclinically, ASG-15ME has demonstrated antitumor activity in models of bladder and lung cancer. The antibody is attached to a potent, synthetic cytotoxic agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLITRK6-expressing tumor cells, resulting in targeted cell-killing. Upon the option exercise, Seattle Genetics will make an option exercise payment and thereafter fund half of the future development costs for the ASG-15ME program. The impact of the option exercise on Astellas' current fiscal year (from April 1, 2013, to March 31, 2014) financial forecast will be immaterial.
Agensys, Inc. and Seattle Genetics Inc. Announces Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer
Jun 4 12
Agensys, Inc. and Seattle Genetics Inc. announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer (CRPC). ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen that is being co-developed by both companies for the treatment of solid tumors. SLC44A4 is an attractive target in prostate cancer and is present in the majority of patients with both localized and metastatic disease. Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC) (Abstract #4568) ASG-5ME is being evaluated in a single-agent phase I clinical trial to determine the maximum tolerated dose (MTD) and to assess the safety, pharmacokinetic profile and antitumor activity of escalating doses of ASG-5ME. At the time of data analysis, 26 patients were enrolled. The median age of the patients was 69.5 years and the median baseline prostate-specific antigen (PSA) level was 82.25. ASG-5ME was given to cohorts of patients with CRPC as a single IV infusion every three weeks at doses ranging from 0.3 milligrams per kilogram (mg/kg) to 3.0 mg/kg. The MTD was exceeded at 3.0 mg/kg. Across all dose cohorts, the most common Grade 1 and 2 adverse events occurring in more than 20% of patients included fatigue (50.0%), decreased appetite (42.3%), peripheral neuropathy (34.6%) and nausea (23.0%). PSA reductions were observed in several patients, providing preliminary evidence of antitumor effect with ASG-5ME treatment. The phase I trial is ongoing, with enrollment to two expansion cohorts in chemotherapy naive and chemotherapy exposed CRPC patients planned. Seattle Genetics and Agensys recently completed enrollment in a phase I pancreatic cancer trial of ASG-5ME dosed weekly. The companies plan to evaluate ASG-5ME in patients with gastric cancer based on preclinical expression data. ASG-5ME is an ADC composed of a fully human antibody directed to SLC44A4, a solute carrier antigen family member identified by Agensys to be overexpressed in epithelial cancers, including more than 80% of samples derived from patients with prostate, pancreatic and gastric cancers. The antibody is attached to monomethyl auristatin E (MMAE) via an enzyme-cleavable linker using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLC44A4-expressing tumor cells, resulting in targeted cell-killing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|